soligenix, inc. is a late stage biopharmaceutical company committed to developing products that address unmet medical needs in the areas of inflammation, oncology and biodefense. soligenix has two areas of focus: 1) a therapeutics segment dedicated to the development of products for orphan diseases and areas of unmet medical need such as cutaneous t-cell lymphoma, oral mucositis, pediatric crohn's disease, acute radiation enteritis, and 2) a vaccines/biodefense segment to develop vaccines and therapeutics for military and civilian applications in the areas of ricin exposure, anthrax exposure, gastrointestinal acute radiation syndrome, and melioidosis.
Company profile
Ticker
SNGX
Exchange
Website
CEO
Christopher Schaber
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
DOR BIOPHARMA INC, ENDOREX CORP, IMMUNOTHERAPEUTICS INC
SEC CIK
Corporate docs
Subsidiaries
Enteron Pharmaceuticals, Inc. • Orasomal Technologies Inc. • Soligenix BioPharma Canada Incorporated • Soligenix UK Limited • Soligenix NE B.V. • Soligenix Biopharma HI, Inc. ...
IRS number
411505029
SNGX stock data
Latest filings (excl ownership)
DEFA14A
Additional proxy soliciting materials
22 Sep 23
8-K
Submission of Matters to a Vote of Security Holders
22 Sep 23
DEFA14A
Additional proxy soliciting materials
15 Sep 23
8-K
Changes in Registrant's Certifying Accountant
15 Sep 23
S-3
Shelf registration
30 Aug 23
10-Q
2023 Q2
Quarterly report
21 Aug 23
NT 10-Q
Notice of late quarterly filing
14 Aug 23
ARS
2022 FY
Annual report to shareholders
7 Aug 23
DEFA14A
Additional proxy soliciting materials
7 Aug 23
DEF 14A
Definitive proxy
7 Aug 23
Latest ownership filings
Financial summary
| Quarter (USD) | Jun 23 | Mar 23 | Dec 22 | Sep 22 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
|---|---|---|---|---|---|---|
| Cash on hand (at last report) | 13.16 mm | 13.16 mm | 13.16 mm | 13.16 mm | 13.16 mm | 13.16 mm |
| Cash burn (monthly) | (no burn) | 583.06 k | 543.44 k | 908.35 k | 641.11 k | 914.31 k |
| Cash used (since last report) | n/a | 1.65 mm | 1.53 mm | 2.56 mm | 1.81 mm | 2.58 mm |
| Cash remaining | n/a | 11.52 mm | 11.63 mm | 10.60 mm | 11.35 mm | 10.58 mm |
| Runway (months of cash) | n/a | 19.8 | 21.4 | 11.7 | 17.7 | 11.6 |
Institutional ownership, Q2 2023
21.6% owned by funds/institutions
| 13F holders | Current |
|---|---|
| Total holders | 20 |
| Opened positions | 5 |
| Closed positions | 2 |
| Increased positions | 1 |
| Reduced positions | 4 |
| 13F shares | Current |
|---|---|
| Total value | 990.40 mm |
| Total shares | 2.12 mm |
| Total puts | 0.00 |
| Total calls | 0.00 |
| Total put/call ratio | – |
| Largest owners | Shares | Value |
|---|---|---|
| Sabby Management | 814.25 k | $573.07 mm |
| Altamont Phamaceutical | 678.34 k | $1.05 mm |
| Anson Funds Management | 514.14 k | $361.86 mm |
| Vanguard | 26.77 k | $18.84 mm |
| First Wilshire Securities Management | 23.33 k | $16.00 k |
| Geode Capital Management | 20.92 k | $14.53 mm |
| Virtu Financial | 14.14 k | $10.00 k |
| Warberg Asset Management | 10.00 k | $7.04 mm |
| Tower Research Capital | 6.89 k | $4.85 mm |
| Plante Moran Financial Advisors | 4.78 k | $3.36 mm |
Recent insider trades
| Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
|---|---|---|---|---|---|---|---|---|---|---|
| 3 May 23 | Timothy R. Cote | Stock Option COMMON STOCK | Grant | Acquire A | No | No | 1.42 | 15,000 | 21.30 k | 15,000 |
| 8 Dec 22 | Christopher J Schaber | Option Common Stock | Grant | Acquire A | No | No | 0.54 | 140,000 | 75.60 k | 140,000 |
| 8 Dec 22 | Jonathan L. Guarino | Option Common Stock | Grant | Acquire A | No | No | 0.54 | 80,000 | 43.20 k | 80,000 |
| 8 Dec 22 | Oreola Donini | Option Common Stock | Grant | Acquire A | No | No | 0.54 | 80,000 | 43.20 k | 80,000 |
News
12 Health Care Stocks Moving In Wednesday's After-Market Session
20 Sep 23
12 Health Care Stocks Moving In Friday's Pre-Market Session
8 Sep 23
Why Smith & Wesson Brands Shares Are Trading Higher By 12%; Here Are 20 Stocks Moving Premarket
8 Sep 23
Soligenix Q2 EPS $(0.22) Beats $(0.49) Estimate, Sales $200.00K Inline
21 Aug 23
Stocks That Hit 52-Week Lows On Monday
14 Aug 23
Press releases
Soligenix, Inc. Announces Adjournment of Annual Meeting, Information for Reconvened Annual Meeting and Additional Proposal to be Considered by Stockholders
22 Sep 23
Soligenix Announces Recent Accomplishments And Second Quarter 2023 Financial Results
21 Aug 23
BioVie and Soligenix Interviews to Air on the RedChip Money Report(R) on Bloomberg TV
11 Aug 23
HyBryte™ Expanded Treatment Trial in Cutaneous T-Cell Lymphoma Opens Enrollment
10 Aug 23
Soligenix Announces Expansion of SGX302 (Synthetic Hypericin) Phase 2a Study in Mild-to-Moderate Psoriasis
11 Jul 23